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There are limited data on the relative efficacy and safety of
calcineurin inhibitors and alkylating agents for idiopathic
steroid-resistant nephrotic syndrome in children. To
clarify this, we compared tacrolimus and intravenous
cyclophosphamide therapy in a multicenter, randomized,
controlled trial of 131 consecutive pediatric patients with
minimal change disease, focal segmental glomerulosclerosis,
or mesangioproliferative glomerulonephritis, stratified for
initial or late steroid resistance. Patients were randomized to
receive tacrolimus for 12 months or 6-monthly infusions of
intravenous cyclophosphamide with both arms receiving
equal amounts of alternate-day prednisolone. The primary
outcome of complete or partial remission at 6 months, based
on spot urine protein to creatinine ratios, was significantly
higher in children receiving tacrolimus compared to
cyclophosphamide (hazard ratio 2.64). Complete remission
was significantly higher with tacrolimus (52.4%) than with
cyclophosphamide (14.8%). The secondary outcome of
sustained remission or steroid-sensitive relapse of nephrotic
syndrome at 12 months was significantly higher with
tacrolimus than cyclophosphamide. Treatment withdrawal
was higher with cyclophosphamide, chiefly due to systemic
infections. Compared to cyclophosphamide, 3 patients
required treatment with tacrolimus to achieve 1 additional
remission. Thus, tacrolimus and prednisolone are effective,
safe, and preferable to cyclophosphamide as the initial therapy
for patients with steroid-resistant nephrotic syndrome.
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The management of children with idiopathic steroid-resistant
nephrotic syndrome is difficult, and there is no consensus on
the most appropriate therapy.1,2 The aim of treatment is
complete or partial remission of proteinuria, the most
important predictor of long-term outcome.3,4 Although a
report from the International Study of Kidney Diseases in
Children showed no benefit with oral cyclophosphamide,5
results from case series6,7 and small trials8,9 suggest that
therapy with intravenous (i.v.) pulse cyclophosphamide is
effective in 40–60% patients with steroid-resistant nephrotic
syndrome. Although the use of i.v. cyclophosphamide carries
risks of infections and gonadotoxicity, these results empha-
size the need for a prospective evaluation of this agent.
Therapy with cyclosporine has shown higher efficacy, with
remission rates of 70–80%,10–12 but it is prolonged, expensive,
and requires monitoring for nephrotoxicity and other adverse
effects.13,14 Although results from case series15,16 and a ran-
domized study17 suggest that tacrolimus has comparable efficacy
and less cosmetic side effects, this has not been examined in a
large controlled study. In view of limited comparative data
on the efficacy of various medications, we prospectively
evaluated the efficacy and safety of therapy with tacrolimus
and alternate-day prednisolone compared with i.v. cyclopho-
sphamide and alternate-day prednisolone in patients with
idiopathic steroid-resistant nephrotic syndrome.
RESULTS
Patient description
Of the 173 patients screened, 42 were excluded (Figure 1). Of
those enrolled, 66 were randomized to the tacrolimus group
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and 65 to the cyclophosphamide group. Primary outcome
was assessed in 124 patients, as 7 did not return after the first
visit. One patient in the cyclophosphamide group was lost to
follow-up after 5 months, and three did not return after the
8- to 10-month visits. Baseline characteristics were similar in
the groups (Table 1); the cohort included 65.7% boys, and
61.8% had initial resistance. Minimal change disease and
focal segmental glomerulosclerosis (FSGS) were present in
59.5% and 32.8% cases, respectively.
Therapy
All patients received the allocated intervention. The dose of
tacrolimus and cyclophosphamide was 0.12±0.03mg/kg/day
and 554.1±98.2mg/m2/dose, respectively. The trough level
of tacrolimus at 4 weeks was 5.8±1.9 ng/ml. The dose of
enalapril was 5.8±2.1 and 5.5±2.3mg/day in tacrolimus and
cyclophosphamide groups, respectively. The respective cumu-
lative doses of prednisolone were 0.44±0.19 and 0.39±
0.19mg/kg/day for the first 6 months (P¼ 0.18), and 0.35±
0.15 and 0.34±0.12mg/kg/day for 12 months (P¼ 0.74).
Primary outcome. The primary outcome variable of the
proportion of patients in complete or partial remission at 6
months was significantly higher with tacrolimus (82.5%)
as compared with cyclophosphamide (45.9%; Po0.001,
Table 2). The proportion of patients showing complete
remission was also higher with tacrolimus (52.4%) compared
with cyclophosphamide (14.8%; Po0.001).
The frequency of treatment failure was lower with
tacrolimus (17.4%) than with cyclophosphamide (54.1%;
Po0.001). In all, 10 of 11 treatment failures with tacrolimus
and 23 of 33 failures with cyclophosphamide were due to
nonresponse to therapy at 6 months. Therapy was withdrawn
in one patient in the tacrolimus group and two in the
cyclophosphamide group owing to a decline in the
glomerular filtration rate (GFR). Eight patients withdrew
therapy with cyclophosphamide (one patient after 2 pulses;
three each after 3 and 4 pulses; one after 5 pulses) because of
recurrent serious infections.
Survival analysis. Patients receiving tacrolimus showed a
higher probability of complete or partial remission compared
with cyclophosphamide (log-rank Po0.001; hazard ratio
(HR) 2.64; 95% confidence interval (95% CI) 1.67–4.19
(Po0.001);Figure 2). The mean time to remission was
3.5±1.7 months with tacrolimus and 4.5±1.7 months with
cyclophosphamide. The likelihood of remission was higher
with minimal change disease (HR 1.74; 95% CI 1.08–2.80,
P¼ 0.02) when compared with FSGS and mesangioprolifera-
tive glomerulonephritis. Other baseline characteristics did
not affect the outcome. The benefit of tacrolimus in terms of
attaining remission was maintained after adjustments for
type of resistance and histopathology (adjusted HR 2.61; 95%
CI 1.59–4.26, Po0.001).
Subgroup analysis. For patients receiving tacrolimus,
complete or partial remission within the subgroup of initial
or late resistance was achieved in 33 (84.61%) versus 19
Screened for eligibility, 173
Excluded, 42
Prior therapy, 14
Ineligible histopathology, 11
Declined consent, 4
Staying far, 9
Inability to swallow tacrolimus, 4Randomized, 131
Assigned to Tacrolimus, 66
Received intervention, 66
Assigned to Cyclophosphamide, 65
Received intervention, 65
Allocation
Follow up and Analysis
Included in primary analysis, 63 
Primary analysis at 6 months, 124
Treatment  failure, 11
Nonresponse, 10
Treatment  withdrawal, 1
(decline in GFR*)
Treatment  failure, 33
Nonresponse, 23
Treatment  withdrawal, 10
(infections 8; decline in GFR*2)
Included in primary analysis, 61
Included in secondary analysis, 52 Included in secondary analysis, 28
Secondary analysis at 12 months, 80
Discontinued intervention, noneDiscontinued  intervention, 1
(decline in GFR*)
Figure 1 |Participant flow. Seven patients were lost to follow-up
(tacrolimus group, three; cyclophosphamide group, four) after the
first visit and were not included in the intention-to-treat analysis.
Patients with treatment failure at 6 months were not included in
the secondary analysis. *Decline in estimated glomerular filtration
rate to o50ml/min per 1.73m2.
Table 1 | Baseline demographic and clinical characteristics
Characteristic
Tacrolimus,
66
Cyclophosphamide,
65
P-
value
Age at enrollment, months 62.1±39.1 74.5±43.9 0.08
Boys 41 45 0.39
Weight, kg 18.74±8.58 19.9±9.41 0.46
Weight SDSa 0.32±1.57 0.72±1.39 0.33
Height, cm 101.69±19.89 107.86±23.44 0.16
Height SDSa 1.53±1.93 1.49±2.19 0.31
Illness before
enrollment, months
13.9±18.2 17.8±29.9 0.36
Initial/late resistance 42b/24 39b/26 0.66
Histopathology
Minimal change disease 44 34 0.09
Focal segmental
glomerulosclerosis
17 26 0.08
Not otherwise
specified/hilar
16/1 24/2
Mesangioproliferative
glomerulonephritis
5 5 0.9
Laboratory
Serum creatinine, mg/dl 0.53±0.12 0.51±0.23 0.21
Serum albumin, g/dl 2.2±0.7 2.3±0.7 0.45
Serum cholesterol, mg/dl 376.0±148.3 354.7±139.8 0.41
eGFRc, ml/min per 1.73m2 93.6±33.2 92.1±30.5 0.77
Urine protein/
creatinined, mg/mg
6.50±4.8 5.3±2.9 0.27
aWeight standard deviation score (SDS) and height SDS were calculated using WHO
Antroplus version 1.0.4.
bNPHS2 gene sequencing in 21 patients with initial resistance showed 2
heterozygous (R229Q) mutations and 1 compound heterozygous mutation
(p.R229Q/p.A308T). No mutations were detected in WT-1 gene.
cGlomerular filtration rate estimated by the equation: 0.413 (height/serum
creatinine; see ref. 24).
dFirst morning spot urine sample.
Values are expressed as means±s.d.
Groups were compared using t-test for continuous variables and w2 test for
categorical variables. There were no significant differences between the two
treatment groups with respect to any characteristic.
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(79.16%) patients, respectively (P-value¼ 0.58). The like-
lihood of remission was significantly higher with tacrolimus
within the subgroups of initial resistance (HR 2.78, 95% CI
1.54–5.03, P¼ 0.001), late resistance (HR 2.35, 95% CI
1.11–4.97, P¼ 0.02), minimal change disease (HR 2.37, 95%
CI 1.32–4.23, P¼ 0.004), and FSGS (HR 2.54, 95% CI
1.09–5.93, P¼ 0.03; Figure 3).
Secondary outcome. Of the 80 patients with complete or
partial remission at 6 months, remission was sustained in
more patients receiving tacrolimus (73.1%) compared with
cyclophosphamide (42.9%; P¼ 0.002; Table 2). All patients
attaining complete remission (tacrolimus, 33; cyclopho-
sphamide, 9) showed favorable outcome (sustained remission
or steroid-sensitive illness) at 12 months. Of the 38 patients
in partial remission (tacrolimus, 19; cyclophosphamide, 19),
22 had nonnephrotic proteinuria, 12 showed favorable outcome,
3 had recurrent steroid resistance, and 1 showed decline in
GFR. The odds of a 12-month favorable outcome were higher
with tacrolimus (OR 3.33; 95% CI 1.24–8.90, P¼ 0.016).
Change in proteinuria. Urine protein to creatinine ratio
(Up/Uc, mg/mg) in tacrolimus and cyclophosphamide
groups was 3.1±3.8 versus 3.2±2.4 (P¼ 0.87) at 2 months,
1.4±2.9 versus 6.5±8.8 (P¼ 0.01) at 4 months, and 0.9±1.5
versus 2.5±4.1 (P¼ 0.01) at 6 months, respectively. The
former showed higher decline in protein excretion from
baseline until 6 months (tacrolimus 6.3±8.7 vs. cyclopho-
sphamide 2.3±4.7; P¼ 0.01).
Estimated GFR. The decline in GFR o50ml/min per
1.73m2 occurred in two patients each with tacrolimus and
cyclophosphamide. At 12 months, the GFR had declined by 9
and 1.5ml/min per 1.73m2, respectively; the differences
were not significant either from baseline (P¼ 0.24) or
between groups (P¼ 0.64).
Number needed to treat. As compared with i.v. cyclopho-
sphamide, three patients were required to be treated with
tacrolimus and alternate-day prednisolone in order to
achieve one additional complete or partial remission.
Safety and tolerability
Ten patients receiving cyclophosphamide had adverse events,
resulting in withdrawal of treatment. Persistent nephrotoxi-
city necessitating tacrolimus discontinuation was seen in two
cases and reversible toxicity in seven. Serious infections were
higher with cyclophosphamide (16 episodes in 8 patients,
including 1 death) compared with tacrolimus (4 episodes in 4
patients; P¼ 0.004; Table 3). No patients had hyperglycemia,
neutropenia, or alopecia.
Table 2 | Primary and secondary outcomes
Primary (6-month) outcome
Tacrolimus,
63
Cyclophosphamide,
61 P-value
Remission 52 (82.5) 28 (45.9) o0.001
Complete 33 (52.4) 9 (14.8) o0.001
Partial 19 (30.1) 19 (31.1) 0.90
Treatment failure 11 (17.4) 33 (54.1) o0.001
Nonresponse 10 23
Withdrawal of therapy 1 10
41 serious infection 0 8
Declining GFRa 1 2
Secondary (12-month)
outcome
Tacrolimus,
52
Cyclophosphamide,
28
P-value
Sustained remission 38 (73.1) 12 (42.9) 0.002
Steroid-sensitive course 2 2
Nonnephrotic proteinuria 11 (21.2) 11 (39.3) 0.08
Resistant nephrotic syndrome 0 3
Withdrawal of therapy 1 0
aDecline in estimated glomerular filtration rate (GFR) to o50ml/min per 1.73m2.
Values in parentheses show percentages.
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Figure 2 |Kaplan–Meier curve showing the probability of
attaining complete or partial remission. The intention-to-treat
population, comprising 124 patients, showed a significantly
higher probability of complete or partial remission with
tacrolimus and alternate-day prednisolone. P-value (log rank)
o0.001. Data were censored at 5 months in one patient lost to
follow-up thereafter.
Subgroup Hazard ratio for remission P-value
Cyclophosphamide better Tacrolimus better
<0.001
0.02
0.004
0.03
<0.001
Initial resistance
Late resistance
Minimal change disease
Focal segmental glomerulosclerosis
All patients
Figure 3 | Forest plot showing the comparative efficacy of
tacrolimus to intravenous (i.v.) cyclophosphamide, as
ascertained by complete or partial remission at 6 months, in
subgroups of patients with steroid-resistant nephrotic
syndrome. The horizontal bars represent 95% confidence
intervals.
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DISCUSSION
The results of this trial show that treatment with tacrolimus
and alternate-day prednisolone was effective and safe in
inducing and sustaining remission in patients with newly
diagnosed, steroid-resistant nephrotic syndrome. A higher
proportion of patients treated with tacrolimus (82.5%)
achieved complete or partial remission at 6 months
compared with i.v. cyclophosphamide (45.9%); a majority
of the former had favorable outcome at 12 months.
Compared with therapy with i.v. cyclophosphamide, one
additional remission was achieved for every three patients
who received tacrolimus. Although this study provides the
first prospective comparison between tacrolimus and i.v.
cyclophosphamide, a recent report showed that therapy with
the former resulted in remission in 11 of 17 adults with
steroid- and cyclophosphamide-resistant nephrotic syndrome.18
Another report on 19 children with diverse renal histologies
showed that tacrolimus achieved complete remission in 11,
including those unresponsive to cyclophosphamide.19
Although the efficacy of cyclosporine for resistant
nephrotic syndrome has been shown previously,10–12 the
need for prolonged therapy and risk of nephrotoxicity has
prompted evaluation of other agents. A National Institutes of
Health (NIH) study compared the efficacy of 12 months of
treatment with cyclosporine with a combination of dex-
amethasone and mycophenolate mofetil in 138 patients with
FSGS.20 Both groups showed similar benefits in attaining at
least partial remission (cyclosporine 46%; combination
33%), and the study failed to demonstrate an unambiguous
benefit with cyclosporine. The Arbeitsgemeinschaft fu¨r
Pa¨diatrische Nephrologie (APN) group compared cyclospor-
ine with i.v. cyclophosphamide in 32 children with steroid
resistance.21 Although cyclosporine induced partial remission
in 60% patients compared with 17% with the latter, inference
was limited as patients who did not respond by 12 weeks were
excluded. A randomized study, on children with steroid-
resistant nephrotic syndrome, showed that tacrolimus and
cyclosporine had similar efficacy (remission in 85.7% and
80% patients, respectively).17 Therapy with tacrolimus was
associated with fewer relapses, less cosmetic effects, and lower
incidence of hypertension.
This study shows that almost one-half of the patients
treated with tacrolimus have complete remission compared
with 14.8% with cyclophosphamide. These findings are
contrary to the low rates of complete remission with
cyclosporine in the NIH-FSGS trial (19%) and APN study
(13.3%), but similar to those previously reported at this
center (cyclosporine 50%; tacrolimus 42.8%).17 All patients
with complete remission at 6 months had a favorable
outcome at 12 months, confirming that complete remission
was valuable in the long-term management of patients.3,4 The
12-month outcome was also satisfactory in patients with
partial remission, with most showing complete remission or
nonnephrotic proteinuria. A similar benefit of partial
response in slowing the rate of progression and improving
renal survival was reported previously in 281 patients with
FSGS from the Toronto Glomerulonephritis Registry.22
The chief adverse events were acute nephrotoxicity with
tacrolimus and serious infections with cyclophosphamide.
Most episodes of nephrotoxicity responded to dose reduc-
tion, and tacrolimus discontinuation was rarely required. In
the APN study, four patients not responding to therapy with
cyclosporine showed decline in renal functions.21 The NIH-
FSGS study reported significantly lower median GFR at 26
weeks in patients receiving cyclosporine compared with those
receiving mycophenolate mofetil. Although in this study data
at 12 months were available only for those in remission,
patients receiving tacrolimus showed a 10% reduction in
GFR compared with the baseline. Future research should
examine the role of biomarkers for detecting early toxicity
and whether alternative agents can sustain tacrolimus-
induced remission.
This study has certain limitations. It was not stratified
based on renal histology, although there was equal distribu-
tion of histopathologies in both arms. However, although the
NIH trial was limited to patients with FSGS,20 we also
included patients with minimal change disease. Although not
powered for subgroup analysis, we found that therapy with
tacrolimus was effective in patients with minimal change
disease and FSGS. Second, although detailed genetic evalua-
tion before enrollment would have been appropriate, this was
carried out only in few patients with initial resistance.
Experience from this center suggests that the proportion of
patients with mutations in NPHS2 and WT1 genes is
relatively low (Sinha et al., abstract presented at ISN
Forefronts Symposium, 22–25 September 2011 in Aarhus,
Denmark). The strengths of this adequately sized trial were
that randomization, data collection, and analysis were
performed centrally. The baseline characteristics were well
balanced, and a widely accepted definition of steroid
resistance was used. Safety monitoring was ensured and
nonresponders were managed appropriately. The results of
this study on children with initial and late resistance and
Table 3 | Adverse events and serious adverse events
Event Tacrolimus, 66 Cyclophosphamide, 65
Any adverse event 45 54
Any serious adverse event 9 19
Persistent nephrotoxicity 2 —
Reversible nephrotoxicity 7 —
Serious infectionsa 4 16
Lower respiratory tract 3 8b
Peritonitis 1 8
Anasarca; hospitalization 3 3
Minor infectionsc 27 24
Seizuresd 1 —
Headached 1 —
Cystitis — 2
Vomiting — 9
aAll managed during hospital stay.
bOne patient died.
cIncludes upper respiratory tract infections and gastroenteritis.
dNeuroimaging (magnetic resonance imaging) was normal.
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major biopsy diagnoses are therefore generalizable. Therapy
with tacrolimus and low-dose prednisolone should be
preferred to cyclophosphamide as the initial therapy for
patients with steroid-resistant nephrotic syndrome, as it is
effective and safe in inducing and maintaining remission of
proteinuria.
MATERIALS AND METHODS
Study design
This prospective, investigator-initiated, open-label, randomized,
controlled trial compared the efficacy of tacrolimus with i.v.
cyclophosphamide in combination with prednisolone for inducing
remission in patients with steroid-resistant nephrotic syndrome.
Patients were enrolled from March 2008 to September 2010 in
pediatric nephrology units of five centers. An Ethics Committee at
each site approved the study protocol. Either the parent or guardian
provided written informed consent. The study was conducted in
accordance with the original protocol and had no amendments. This
study report complies with the Consolidated Standards of Reporting
Trials statement.23
The coordinating center (All India Institute of Medical Sciences,
New Delhi) conceived and designed the study protocol. Investigators
at the coordinating center vouch for the accuracy and completeness
in collation and analysis of data. The manuscript was reviewed,
edited, and approved by all authors.
Study participants
Patients, 2–16 years old, with newly diagnosed initial or late steroid-
resistant nephrotic syndrome and renal histological features
suggestive of minimal change disease, FSGS, or mesangioprolifera-
tive glomerulonephritis were eligible. Initial resistance was the
absence of remission despite therapy with prednisolone at 2mg/kg/
day (maximum 60mg) for 4 weeks; patients with remission at onset
but steroid resistance in a subsequent relapse were defined as late
resistance. We included patients with an early-morning Up/Uc of
42.0 or the presence of 3þ /4þ proteinuria by dipstick test.
Patients with any of the following were excluded: (1) impaired
renal function (estimated GFR o60ml/min per 1.73m2);24 (2)
intake of immunosuppressive medications other than prednisolone
in the preceding 6 months in patients with late resistance; (3) prior
therapy with cyclophosphamide or calcineurin inhibitors; (4)
infection with hepatitis B or C, or HIV; (5) IgA nephropathy or
collapsing glomerulopathy; and (6) inability to swallow tacrolimus
capsules.
Permuted block randomization with stratification, by initial or
late resistance, was performed centrally by individuals not involved
in trial implementation. The investigators were blinded to the
randomization schedules and allocation was concealed in opaque
sealed envelopes.
Intervention
Patients were allocated in a 1:1 ratio to receive therapy with either
tacrolimus at a dose of 0.1–0.15mg/kg/day for 12 months (Pangraf;
Panacea, Mumbai, India; 0.5 and 1mg capsules) or i.v. cyclopho-
sphamide at 500mg/m2 once a month for 6 doses. Prednisolone was
given at a dose of 1.5mg/kg every other day for 2 weeks, and then
tapered by 0.25mg/kg every 2 weeks to 0.5mg/kg on alternate days
for 12 months. Dosing was based on recent body weight. All patients
received treatment with enalapril (maximum 10mg) and calcium
supplements.
Dose adjustments with tacrolimus. Trough (12 h) levels were
measured, using microparticle enzyme immunoassay, 2 weeks after
beginning therapy or in the presence of acute nephrotoxicity. Dose
adjustments, by 20–25%, were performed every 7–10 days until a
tacrolimus level of 5–7ng/ml was achieved; lower levels were accepted if
patients were in remission. At each visit, a 1- to 2-month supply of
tacrolimus was given and treatment adherence was assessed by pill
count of the returned packs. Reversible nephrotoxicity was defined as
430% increase in the level of serum creatinine from the baseline,
which improved within 2 weeks of reduction of tacrolimus dose.
Administration of cyclophosphamide. Cyclophosphamide was
diluted in 200ml normal saline and infused over 2 h. Coadminis-
tered medications included 2-mercaptoethane sulfonate sodium
(same dose as cyclophosphamide; 20% i.v., 80% orally) and
ondansetron (0.5mg/kg i.v.).
Outcomes and follow-up
Parents were instructed to examine the first morning urine specimen
for proteinuria by dipstick daily. Visits were scheduled once a month
until 6 months, and then every 2 months until 12 months. At each
visit, protocol-defined efficacy and safety parameters were reviewed.
The Up/Uc ratio was measured on the first morning sample. Blood
counts and levels of creatinine, albumin, cholesterol, glucose, and
electrolytes were measured at each visit.
The primary efficacy end point, at 6 months, was the occurrence
of complete or partial remission. Complete remission was defined as
Up/Uc o0.2, confirmed once within the next 3 days; partial
remission was Up/Uc 0.2–2, the absence of edema, and serum
albumin 42.5 g/dl. Nonresponse was defined as Up/Uc 42, the
presence of edema, or serum albumin o2.5 g/dl. Nonresponders
exited the study at 6 months.
For those attaining remission, secondary end points at 12
months were as follows: (1) proportion of patients in sustained
remission (Up/Uc o0.2) or with steroid-sensitive nephrotic
syndrome, (2) subjects with nonnephrotic proteinuria (Up/Uc
0.2–2, no edema, albumin 42.5 g/dl) or recurrence of steroid
resistance, (3) frequency and type of side effects, and (4) estimated
GFR. The presence of sustained remission or steroid-sensitive course
at 12 months was considered a favorable outcome.
Treatment of relapses. In patients achieving either complete
or partial remission, relapse was the presence of 3–4þ proteinuria
by dipstick for 3 consecutive days. These patients were treated with
prednisolone, at 2mg/kg/day until remission (trace/negative protein
for 3 days), followed by 1.5mg/kg on alternate days for 2 weeks and
then tapered.
Management of serious infections. Serious infections (for
example, pneumonia, peritonitis, and cellulitis) were those that
required hospitalization and were treated using standard protocols.
Patients received prednisolone (0.2–0.3mg/kg/day orally) or an
equivalent dose of i.v. hydrocortisone during these infections.
Safety measures
Safety assessments included clinical and laboratory assessments, and
monitoring for serious adverse events, including by the Data and
Safety Monitoring Board. A 6-monthly report was submitted to the
ethics committee. Patients who discontinued study medication were
followed up for adverse events for 30 days after their last dose.
Treatment failure. Treatment failure was as follows: (1)
nonresponse to therapy at 6 months, (2) 41 episode of serious
infection requiring hospitalization, (3) persistent elevation in serum
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creatinine X30% despite dose reduction, and (4) estimated GFR
o50ml/min per 1.73m2.
Statistical analysis
On the basis of occurrence of complete or partial remission in 50%
patients receiving cyclophosphamide,7,9 and assuming that therapy
with tacrolimus would increase the remission rate by 30%, 64
patients were required per group to show significant differences at
90% power, two-tailed a of 5%, and dropout rate of 10%. Data were
analyzed using Stata, version 11.2 (StataCorp 2009; Stata Statistical
Software: Release 11; College Station, TX: StataCorp LP). Con-
tinuous data were expressed as the means±s.d. Categorical data
were analyzed with Pearson’s w2 or Fisher’s exact tests.
Efficacy analyses were performed on the intention-to-treat
population, which included patients who returned for the first
follow-up visit with last value carried forward. The effect of
treatment on primary outcome was estimated by HR obtained from
a Cox regression model. For patients achieving remission, the time
from randomization to first achieving the 6-month response of
either a complete or partial remission was taken for the time-to-
event analysis. Kaplan–Meier survival estimates compared the time
to achievement of remission using log-rank test. Logistic regression
was used to calculate odds ratio for achieving a favorable outcome at
12 months. The number needed to be treated with tacrolimus so as
to achieve one additional remission over that by i.v. cyclopho-
sphamide was calculated.25
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